This is the authors' abstract. We don't add key points for this paper.
Ganoderma species is excessively well-known for a variety of medicinal effects and health benefits by folk experiences, thus often underestimated for componential specification. Ganoderma lucidum methanol-extracted components (1-15) were selected from the literature and subjected for computational evaluations on the anti-diabetic potentiality. As the results, molecular docking simulation suggests the most promising PDB-3W37 (α-glucosidase) inhibitors from the standpoint of static intermolecular interaction, i.e. 1 (DS -12.8 kcal.mol-1; RMSD 1.23 Å) > 2 (DS -12.3 kcal.mol-1; RMSD 1.76 Å) > 11 (DS -12.0 kcal.mol-1; RMSD 1.20 Å) ≈ 13 (DS -12.1 kcal.mol-1; RMSD 1.58 Å); QSARIS confirm their biocompatibility given the physicochemical properties in reference to Lipinski's rule of five; ADMET pharmacokinetics and pharmacology justify their pharmaceutical applicability. Quantum-based retrievals justify their suitability fromthe view of intrinsic chemical properties, i.e: ground-state energy, dipole moment, and band gap: 1 (-1888.85 eV; 9.129 Debye; 5.952 eV), 2 (-1887.64 eV; 6.689 Debye; 6.393 eV), 11 (-1961.62 eV; 5.106 Debye; 3.599 eV), 13 (-1543.14 eV; 8.294 Debye; 4.598 eV). The results encourage experimental attempts for anti-diabetic applications on 1 (Butyl lucidenate P), 2 (Butyl lucidenate E2), 11 (Methyl ganoderate H), and 13 (Methyl lucidenate N).
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Nguyen et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: